SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is at the center of investor focus following a quarterly report that featured record revenue, strong services growth, and a significant 100 billion dollar share buyback authorization. While some market participants are debating the impact of supply constraints and the upcoming leadership transition, the community remains actively divided between those highlighting the company's defensive strength and capital return efficiency versus skeptics questioning its long-term growth and innovation trajectory.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility driven by a short squeeze, as traders react to a shrinking float and rising borrow fees while betting on the company's strategic pivot toward telecommunications infrastructure. The community remains deeply divided between aggressive bulls anticipating a move into triple digits and cautious observers warning of inevitable dilution and the risks of chasing a momentum-driven speculative play.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing extreme volatility as investors react to a significant earnings blowout, where the company smashed revenue and EPS expectations alongside strong future guidance. While bulls celebrate the company's massive profitability and new share buyback program, the stock is seeing a "sell-the-news" reaction, leaving the community sharply divided between those calling for a rapid rebound and others warning that the shares remain overextended.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is trending following a massive quarterly earnings beat that surpassed revenue and EPS expectations, fueling community debate over the company's long-term ad monetization and AI data licensing potential. While some investors remain cautious of potential post-earnings volatility, many are focused on the stock's growth trajectory and whether it will maintain its momentum for S&P 500 inclusion.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as traders navigate extreme volatility driven by escalating geopolitical tensions in the Middle East and shifting sentiment around potential ceasefire negotiations. The community is actively debating the reliability of market-moving news regarding energy supply routes and the impact of these geopolitical developments on leveraged tech-heavy ETFs.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox stock is facing downward pressure following a guidance cut attributed to the company's own age-verification rollout, which has slowed user acquisition and triggered negative sentiment among some investors. While some market participants are debating whether this represents a structural growth plateau or a temporary setback, others remain focused on the potential for long-term engagement growth and platform monetization.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened volatility ahead of earnings as investors weigh positive R2 production milestones and strategic partnerships against concerns over cash burn and potential share dilution. The community remains deeply divided, with bulls focusing on long-term production scaling and industrial partnerships, while bears point to persistent losses and capital structure risks.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to a major pivot toward autoimmune treatments, highlighted by a milestone payment from a Boehringer Ingelheim partnership and an upcoming R&D presentation on their lead candidate CUE-401. Community members are actively debating the company's long-term potential under new leadership against concerns regarding historical performance and potential reverse split volatility.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following a significant beat on both earnings and revenue, with the community actively debating the company's aggressive AI adoption through its 'Rovo' platform versus the long-term impact of its restructuring efforts. Investors are split between optimism over the company's potential to re-rate as a leading enterprise software provider and skepticism regarding future revenue guidance and the broader sustainability of SaaS business models in the current market environment.

What is Chronotech? Chrono.tech provides blockchain-based solutions for recruitment, HR and payment processes, reducing the barriers to accessing work and transferring funds securely in the global labor marketplace. The project’s suite of services - and native governance token TIME - are hosted on multiple blockchains and include LaborX.com, a peer-to-peer freelancer marketplace, TimeX.io, a Plasma-based cryptocurrency exchange; AUDT, an Australian dollar-backed stablecoin; and PaymentX, a crypto invoicing and payroll solution.  TIME token The TIME token is the native token of the Chrono.tech ecosystem and can be used within its products, e.g. to secure premium account status, as well as staking TIME on TimeWarp.finance to receive the revenues generated by all services. In November 2020, the original TIME token was upgraded to the new ERC677 standard, enabling it to be integrated with other DeFi protocols, allowing lower-cost transactions, and providing other advantages, while remaining fully ERC20-compatible. The new TIME 2.0 token contract also included up-to-date metadata about the project.  Chrono.tech products and ecosystem Chrono.tech aims to solve a series of problems in the global recruitment and employment markets. LaborX is Chrono.tech’s freelance work portal. The service allows freelancers and customers to organise work via digital agreements, powered by smart contracts. All payments are escrowed and made in cryptocurrency. Once a job is completed, escrowed payments are released automatically. A dispute resolution service is available in case of disagreement. TimeX is Chrono.tech’s cryptocurrency exchange. TimeX is a hybrid Plasma-based exchange that offers the benefits of both centralised and decentralised technologies. Use of Plasma allows for fast, secure trading of digital assets. The conventional interface provides a user-friendly trading experience. Based in Australia, TimeX is licensed and compliant with rules and best practices required by AUSTRAC, the country’s financial intelligence agency. TimeX is listed on CoinMarketCap https://coinmarketcap.com/exchanges/timex/ TimeWarp is the ecosystem’s DeFi yield farming application where TIME holders can stake their token to earn revenues generated by all products of the Chrono.tech product range. All 100% of revenues generated are being distributed to TIME holders on a weekly basis. AUDT is a stablecoin, hosted on the Ethereum blockchain and backed 1:1 with Australian dollars (AUD). Use of AUDT enables traders to move money into and out of the blockchain ecosystem from an Australian bank account, to store value in AUD on the blockchain and transfer funds anywhere in the world, quickly and easily. AUDT is one of the key fiat currencies traded on TimeX. AUDT is fully compliant with AUSTRAC requirements and undergoes regular audits conducted by a licensed, third party accounting firm. PaymentX is a multi-currency crypto payroll solution that enables individuals as well as businesses to integrate crypto payments into their day-to-day invoice processes. Contractors can submit professional invoices and specify a crypto wallet for payment. Companies can pay multiple invoices with one click, while the software converts the dollar-equivalent amount due into crypto automatically at the point of transaction, avoiding the need for manual calculations. TimeBridge is an in-house developed multi-blockchain tokenbridge that supports multiple blockchains such as Ethereum and BSC. It allows transferring of TIME tokens between networks.

Chronobank

Chronobank ($TIME) is attracting significant attention due to its extremely low circulating supply of approximately 710,000 tokens, leading to intense community speculation about potential supply shocks and price volatility. Traders are actively comparing its low market cap and historical performance to other small-cap runners, with many expressing bullish sentiment while some warn of the risks associated with the token's thin order books and pattern of rapid price spikes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The $30 million net proceeds from the placement will allow the company to advance its clinical pipeline, Cue said.</li><li>Cue also announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases.</li><li>The company named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.</li></ul> Shares of Cue Biopharma (CUE) jumped nearly 100% after-hours on Thursday after the clinical-stage biotech company announced changes collectively aimed at strengthening its cash position, expanding its clinical pipeline, and bringing in new leadership.The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.<h2 class="st-heading-2">$30 Million Private Placement Bolsters Balance Sheet</h2>Cue Biopharma entered into a securities purchase agreement with certain accredited investors for a private placement expected to raise gross proceeds of approximately $30 million before fees and expenses.The company stated it will use the net proceeds to advance its clinical pipeline, support working capital, and fund general corporate purposes. The transaction is expected to close on or about May 4, 2026, subject to customary closing conditions.<h2 class="st-heading-2">Exclusive License Adds To Pipeline</h2>Cue Biopharma further announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases. The license covers all territories except mainland China, Hong Kong, Macau, and Taiwan.Cue plans to advance the asset into further studies, with near-term clinical data expected from an ongoing mid-stage trial in chronic spontaneous urticaria during the second half of 2026.The company said that it will pay Ascendant $15 million upfront as a license fee, followed by up to an aggregate of $676.5 million in additional potential payments upon the achievement of certain milestones, in addition to tiered royalties on future sales of the drug.<h2 class="st-heading-2">Veteran Executive Shao-Lee Lin Named New CEO</h2>Cue Biopharma also named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.Lin previously founded and led the pharma company ACELYRIN, where she raised over $1 billion in capital and took the company public at a valuation exceeding $2 billion within three years. She has held senior roles at Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen.<h2 class="st-heading-2">How Did CUE Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user voiced optimism on the licensing deal.<stembedurl>https://www.stocktwits.com/AlertsAndNews/message/651957851</stembedurl>Another use voiced hopes for the stock rallying as high as $50, implying a potential rally of about 100% from the stock’s last close.<stembedurl>https://www.stocktwits.com/Aburose/message/651956517</stembedurl>A third user opined that the after-hours rally was a result of manipulation and a short squeeze.<stembedurl>https://www.stocktwits.com/Erect4tech/message/651956070</stembedurl><a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 35% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/meta-ceo-links-stock-drop-to-higher-capex-plans-team-cuts-and-more-apps-report/cZBMpgSReIX">Meta CEO Links Stock Drop To Higher Capex, Plans Team Cuts And More Apps: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cue Biopharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? 

The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.

Equity

The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.


Cue Biopharma (NASDAQ:CUE) Raised to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Cue Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday...

Cue Biopharma (NASDAQ:CUE) Shares Gap Down - Here's Why

Cue Biopharma (NASDAQ:CUE) Shares Gap Down - Here's Why...

What's Behind The Drop In Cue Biopharma Stock Today?

Cue Biopharma, Inc. (NASDAQ:CUE) shares are tumbling on Wednesday after the company announced a reverse stock split.read more...

<ul><li>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025.&nbsp;</li><li>The company added on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development and commercial milestone-based payments.&nbsp;</li><li>CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic.</li></ul>Shares of Cue Biopharma, Inc. (CUE) is on track to record its best session to date, if gains hold, after the company announced earlier this week that it will receive $7.5 million as milestone payment from an agreement with Boehringer Ingelheim.CUE stock is up 77% at the time of writing.<h2 class="st-heading-2">Cue- Boehringer Ingelheim Deal</h2>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025 &nbsp;to develop and commercialize Cue Biopharma’s CUE-501 product candidate for autoimmune diseases.Under the deal, Cue received an upfront payment of $12 million and is eligible to earn up to about $345 million in research, development and commercial milestone-based payments, as well as royalty payments on net sales.The company now expects a $7.5 million payment in May 2026. Cue Biopharma also said on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development, and commercial milestone-based payments.CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic. In February, the company said that its preclinical data demonstrated that CUE-401 was well tolerated with no adverse events.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed optimism about the rally after a quiet period. “This is starting to get interesting,” they wrote<stembedurl>https://www.stocktwits.com/topstockalerts/message/649975686</stembedurl>Another user highlighted the possibility of additional payments under the deal.<stembedurl>https://www.stocktwits.com/Aburose/message/649968775</stembedurl><a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?

Cue now expects a $7.5 million payment from Boehringer Ingelheim in May 2026.

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional milestone potential and pipeline progress.read more...

Get Ready for the Weekend with One of these Strong Runners

Today’s market action is dominated by a bunch of listings we’ve covered this week, plus a few fresh faces, like Cue Biopharma (NASDAQ:CUE), which is running strong after announcing, on Wednesday, that it will receive $7.5 million preclinical milestone payment for its agreement with Boehringer Ingelheim, while Xiao-I (NASDAQ:AIXI) has been in play since providing an update on its Apple (NASDAQ:AAPL) patent infringement lawsuit. $SKYQ, $KBLB, $UCAR, $ELAB, $CUE, $AIXI, $AAPL, $CREG, $RAYA

Shares of Cue Biopharma (CUE) fell 8% in extended trading hours on Friday after the company announced that its top leader Usman Azam has stepped down as president and CEO, effective March 26.Azam also resigned from his role as a director of the company. Azam was appointed into the role in late-September, replacing former CEO Daniel Passeri, and served merely six months in the role. &nbsp;<h2 class="st-heading-2">New CEO</h2>Lucinda Warden has been appointed interim president and CEO, the company said. Warden served as Cue Biopharma’s chief financial and business officer since Feb. 2026, and previously as Cue Biopharma’s chief business officer from Sept. 2024 until Feb. 2026.Prior to working with Cue, Warden was employed with Johnson &amp; Johnson and Janssen Biologics.<h2 class="st-heading-2">Cue Pipeline</h2>Boston, Massachusetts-headquartered Cue Biopharma is now looking to progress CUE-401 into clinical trials by the second half of this year. The investigational drug is the company’s lead asset for the treatment of autoimmune and inflammatory diseases. In preclinical studies, CUE-401 was well tolerated with no adverse events observed.In November, Cue also entered into a collaboration and license agreement with ImmunoScape, Pte. Ltd, a biotechnology company, to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.Under the agreement, ImmunoScape will develop a novel Seed-and-Boost immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers, with ImmunoScape’s proprietary T cell receptors.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CUE Stock Slips As CEO Leaves After Just Six Months In Role

Usman Azam was appointed into the role in late-September, replacing former CEO Daniel Passeri.  

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Traders are highlighting the micro-float volatility after the recent reverse split and its potential for massive swings.

Bullish investors are citing unconfirmed Zacks strong buy reports and $100 price targets to justify current price action.

Skepticism surrounds the $30 million private placement at an $11 effective price point, leading to fears of dilution and manipulation.

CUE
Cue Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CUE News

CUECue Biopharma Inc